Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Johnson & JohnsonNYSE: JNJ

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 2.45B shares rose 0.8% year over year, in line with the +0.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.8% holds above the trailing-twelve-month pace of +0.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
2.45B+0.3% QoQ
Last fiscal yearDec 2025
2.43B+0.0% YoY
LTMSep 2026
2.44B+0.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.8%——
1 year+0.0%——
3-year CAGR-3.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
2.43B USD
Year-over-year change
+0.0%
4-year CAGR
-2.4%

Weighted Avg Shares (Diluted) vs competitors

How JNJ compares with its peers on the latest reported figures

  • JNJ's LTM Sep 2026 weighted avg shares (diluted) of 2.44B shares is the 3rd highest of the 11 companies compared; the peer median is 1.98B shares.
  • Its year-over-year change of +0.8% is the highest of 11, against a peer median of -0.2%.
  • Over three fiscal years its annual growth of -3.0% compares with a peer median of -0.2%.
JNJ Competitors Peer median
Weighted Avg Shares (Diluted) for JNJ and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.71B +0.0%-0.3%
MRKMerck & Co., Inc.LTM Jun 20262.48B -1.9%-0.5%
JNJJohnson & JohnsonLTM Sep 20262.44B +0.8%-3.0%
SNYSanofiLTM Jun 20262.43B -2.4%-0.8%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.3%-1.7%
GSKGSK plcLTM Jun 20262.04B -0.9%+0.3%
NVSNovartis AGLTM Jun 20261.92B -3.4%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.0%-0.1%
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
GILDGilead Sciences, Inc.LTM Jun 20261.25B -0.5%-0.2%
AMGNAmgen Inc.LTM Jun 2026543.25M +0.3%+0.1%
Peer median (excluding JNJ) 1.98B-0.2%-0.2%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.